Designing calcium release channel inhibitors with enhanced electron donor properties: Stabilizing the closed state of ryanodine receptor type 1

Molecular Pharmacology

Volumn 81, Issue 1, 2012, Pages 53-62

  Ye, Yanping ^a   Yaeger, Daniel ^a   Owen, Laura J ^a   Escobedo, Jorge O ^a   Wang, Jialu ^a   Singer, Jeffrey D ^a   Strongin, Robert M ^a   Abramson, Jonathan J ^a  

^a PORTLAND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE DERIVATIVE; 4 METHOXY 3 METHYLPHENOL; ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM CHANNEL BLOCKING AGENT; CHLOROCRESOL; CHLOROCRESOL DERIVATIVE; RYANODINE RECEPTOR 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRON TRANSPORT; ENZYME ACTIVITY; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; RABBIT;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CALCIUM SIGNALING; DRUG DISCOVERY; ELECTRON TRANSPORT; MUSCLE, SKELETAL; PROTEIN STABILITY; RABBITS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; THIAZEPINES;

EID: 84455173448     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.074740     Document Type: Article

References (33)

1. Ahern GP, Junankar PR, and Dulhunty AF (1997) Subconductance states in single-channel activity of skeletal muscle ryanodine receptors after removal of FKBP12. Biophys J 72:146-162. (Pubitemid 27043425)
2. 2+ pumps. Pharmacol Rep 61:838-842.
3. Almassy J, Sztretye M, Lukacs B, Dienes B, Szabo L, Szentesi P, Vassort G, Csernoch L, and Jona I (2008) Effects of K-201 on the calcium pump and calcium release channel of rat skeletal muscle. Pflugers Arch 457:171-183.
4. Bellinger AM, Reiken S, Dura M, Murphy PW, Deng SX, Landry DW, Nieman D, Lehnart SE, Samaru M, LaCampagne A, et al. (2008) Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity. Proc Natl Acad Sci USA 105:2198-2202. (Pubitemid 351439488)
5. Blayney LM, Jones JL, Griffiths J, and Lai FA (2010) A mechanism of ryanodine receptor modulation by FKBP12/12.6, protein kinase A, and K201. Cardiovasc Res 85:68-78.
6. 2+ release channel from skeletal muscle sarcoplasmic reticulum. J Biol Chem 270:25557-25563.
7. Fessenden JD, Feng W, Pessah IN, and Allen PD (2006) Amino acid residues Gln4020 and Lys4021 of the ryanodine receptor type 1 are required for activation by 4-chloro-m-cresol. J Biol Chem 281:21022-21031. (Pubitemid 44115443)
8. Herrmann-Frank A, Richter M, and Lehmann-Horn F (1996) 4-Chloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem Pharmacol 52:149-155. (Pubitemid 26199118)
9. Higgins L, Korzekwa KR, Rao S, Shou M, and Jones JP (2001) An assessment of the reaction energetics for cytochrome P450-mediated reactions. Arch Biochem Biophys 385:220-230. (Pubitemid 32989001)
10. 2+ spark mass. J Mol Cell Cardiol 48:293-301.
11. 3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association. Biochem J 404:431-438.
12. Jacobson AR, Moe ST, Allen PD, and Fessenden JD (2006) Structural determinants of 4-chloro-m-cresol required for activation of ryanodine receptor type 1. Mol Pharmacol 70:259-266.
13. Kaneko N, Ago H, Matsuda R, Inagaki E, and Miyano M (1997) Crystal structure of annexin V with its ligand K-201 as a calcium channel activity inhibitor. J Mol Biol 274:16-20. (Pubitemid 27519452)
14. + current in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 361:646-653.
15. Kohno M, Yano M, Kobayashi S, Doi M, Oda T, Tokuhisa T, Okuda S, Ohkusa T, Kohno M, and Matsuzaki M (2003) A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure 1. Am J Physiol Heart Circ Physiol 284:H1035-H1042. (Pubitemid 36228254)
16. 2+ release channel/ ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 118:2230-2245.
17. Lisy O and Burnett JC Jr (2006) New cardioprotective agent K201 is natriuretic and glomerular filtration rate enhancing. Circulation 113:246-251.
18. MacLennan DH (1970) Purification and properties of an adenosine triphosphatase from sarcoplasmic reticulum. J Biol Chem 245:4508-4518.
19. + channel antagonists act as electron donors while agonists act as electron acceptors with free radicals. FEBS Lett 191:159-162.
20. Marinov BS, Olojo RO, Xia R, and Abramson JJ (2007) Non-thiol reagents regulate ryanodine receptor function by redox interactions that modify reactive thiols 1. Antioxid Redox Signal 9:609-621. (Pubitemid 46598259)
21. 2+ agonists and channel blockers interact in the opposite manner with photogenerated unpaired electrons. FEBS Lett 186:251-254.
22. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, and Marks AR (2000) PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101:365-376.
23. Olojo RO, Xia RH, and Abramson JJ (2005) Spectrophotometric and fluorometric assay of superoxide ion using 4-chloro-7-nitrobenzo-2-oxa-1,3- diazole. Anal Biochem 339:338-344. (Pubitemid 40395292)
24. 2+ release by acting at the apparent physiological release site in sarcoplasmic reticulum. J Biol Chem 259: 13363-13369.
25. Sutherland MW and Learmonth BA (1997) The tetrazolium dyes MTS and XTT provide new quantitative assays for superoxide and superoxide dismutase. Free Radic Res 27:283-289. (Pubitemid 27474887)
26. Trimm JL, Salama G, and Abramson JJ (1986) Sulfhydryl oxidation induces rapid calcium release from sarcoplasmic reticulum vesicles. J Biol Chem 261:16092-16098. (Pubitemid 17202866)
27. Van Lanen SG, Reader JS, Swairjo MA, de Crécy-Lagard V, Lee B, and Iwata-Reuyl D (2005) From cyclohydrolase to oxidoreductase: discovery of nitrile reductase activity in a common fold. Proc Natl Acad Sci USA 102:4264-4269. (Pubitemid 40397100)
28. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, and Knollmann BC (2009) Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15:380-383.
29. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, Coromilas J, Landry DW, and Marks AR (2004) Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304:292-296. (Pubitemid 38452182)
30. Wehrens XH, Lehnart SE, Reiken S, van der Nagel R, Morales R, Sun J, Cheng Z, Deng SX, de Windt LJ, Landry DW, et al. (2005) Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci USA 102:9607-9612. (Pubitemid 40981728)
31. Yamamoto T and Ikemoto N (2002) Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor. Biochem Biophys Res Commun 291: 1102-1108. (Pubitemid 34694387)
32. Yano M, Kobayashi S, Kohno M, Doi M, Tokuhisa T, Okuda S, Suetsugu M, Hisaoka T, Obayashi M, Ohkusa T, et al. (2003) FKBP12.6-mediated stabilization of calcium- release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107:477-484. (Pubitemid 36158052)
33. Zable AC, Favero TG, and Abramson JJ (1997) Glutathione modulates ryanodine receptor from skeletal muscle sarcoplasmic reticulum. Evidence for redox regulation of the Ca2+ release mechanism. J Biol Chem 272:7069-7077. (Pubitemid 27166410)